{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T19:54:03Z","timestamp":1790798043846,"version":"4.1.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2019,12,28]],"date-time":"2019-12-28T00:00:00Z","timestamp":1577491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2019,12,28]],"date-time":"2019-12-28T00:00:00Z","timestamp":1577491200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100007819","name":"Allergan","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007819","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1007\/s40265-019-01248-0","type":"journal-article","created":{"date-parts":[[2019,12,28]],"date-time":"2019-12-28T10:02:26Z","timestamp":1577527346000},"page":"167-179","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":102,"title":["24-Month Phase I\/II Clinical Trial of Bimatoprost Sustained-Release Implant (Bimatoprost SR) in Glaucoma Patients"],"prefix":"10.1007","volume":"80","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2077-659X","authenticated-orcid":false,"given":"E. Randy","family":"Craven","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Walters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William C.","family":"Christie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas G.","family":"Day","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard A.","family":"Lewis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margot L.","family":"Goodkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronica","family":"Wangsadipura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael R.","family":"Robinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Bejanian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"for the Bimatoprost SR Study Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tin","family":"Aung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allen D.","family":"Beck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James D.","family":"Branch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William C.","family":"Christie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Coote","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles J.","family":"Crane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E. Randy","family":"Craven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Crichton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas G.","family":"Day","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Day","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F. Jane","family":"Durcan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard M.","family":"Evans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William J.","family":"Flynn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00e9bastien","family":"Gagn\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damien F.","family":"Goldberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jack V.","family":"Greiner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Jeppsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Delan","family":"Jinapriya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. Starck","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shimon","family":"Kurtz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard A.","family":"Lewis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven L.","family":"Mansberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph R.","family":"Martel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shamira A.","family":"Perera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael H.","family":"Rotberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert M.","family":"Saltzmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Howard I.","family":"Schenker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael E.","family":"Tepedino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Imelda R.","family":"Yap-Veloso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harvey S.","family":"Uy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas R.","family":"Walters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,12,28]]},"reference":[{"key":"1248_CR1","unstructured":"American Academy of Ophthalmology. Preferred practice pattern in primary open-angle glaucoma; 2016. https:\/\/www.aao.org\/preferred-practice-pattern\/primary-open-angle-glaucoma-ppp-2015. Accessed Sep 17, 2019."},{"key":"1248_CR2","unstructured":"European Glaucoma Society. Terminology and guidelines for glaucoma (4th edition); 2014. http:\/\/www.eugs.org\/eng\/EGS_guidelines4.asp. Accessed Oct 18, 2016."},{"key":"1248_CR3","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1136\/bjo.2005.081224","volume":"90","author":"HA Quigley","year":"2006","unstructured":"Quigley HA, Broman AT. The number of people with glaucoma worldwide in 2010 and 2020. Br J Ophthalmol. 2006;90:262\u20137.","journal-title":"Br J Ophthalmol"},{"key":"1248_CR4","doi-asserted-by":"publisher","first-page":"2081","DOI":"10.1016\/j.ophtha.2014.05.013","volume":"121","author":"YC Tham","year":"2014","unstructured":"Tham YC, Li X, Wong TY, Quigley HA, Aung T, Cheng CY. Global prevalence of glaucoma and projections of glaucoma burden through 2040: a systematic review and meta-analysis. Ophthalmology. 2014;121:2081\u201390.","journal-title":"Ophthalmology"},{"key":"1248_CR5","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1016\/j.ajo.2007.02.022","volume":"143","author":"R McKean-Cowdin","year":"2007","unstructured":"McKean-Cowdin R, Varma R, Wu J, Hays RD, Azen SP. Severity of visual field loss and health-related quality of life. Am J Ophthalmol. 2007;143:1013\u201323.","journal-title":"Am J Ophthalmol"},{"key":"1248_CR6","doi-asserted-by":"publisher","first-page":"1763","DOI":"10.1185\/03007990802111068","volume":"24","author":"J Thygesen","year":"2008","unstructured":"Thygesen J, Aagren M, Arnavielle S, Bron A, Frohlich SJ, Baggesen K, et al. Late-stage, primary open-angle glaucoma in Europe: social and health care maintenance costs and quality of life of patients from 4 countries. Curr Med Res Opin. 2008;24:1763\u201370.","journal-title":"Curr Med Res Opin"},{"key":"1248_CR7","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1016\/j.ajo.2011.06.004","volume":"152","author":"R Varma","year":"2011","unstructured":"Varma R, Lee PP, Goldberg I, Kotak S. An assessment of the health and economic burdens of glaucoma. Am J Ophthalmol. 2011;152:515\u201322.","journal-title":"Am J Ophthalmol"},{"key":"1248_CR8","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.ajo.2018.12.021","volume":"200","author":"PY Ramulu","year":"2019","unstructured":"Ramulu PY, Mihailovic A, West SK, Gitlin LN, Friedman DS. Predictors of falls per step and falls per year at and away from home in glaucoma. Am J Ophthalmol. 2019;200:169\u201378.","journal-title":"Am J Ophthalmol"},{"key":"1248_CR9","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1097\/IJG.0000000000000819","volume":"27","author":"AB Miller","year":"2018","unstructured":"Miller AB, Lajoie K, Strath RA, Neima DR, Marigold DS. Coordination of gaze behavior and foot placement during walking in persons with glaucoma. J Glaucoma. 2018;27:55\u201363.","journal-title":"J Glaucoma"},{"key":"1248_CR10","doi-asserted-by":"publisher","first-page":"e8019","DOI":"10.1097\/MD.0000000000008019","volume":"96","author":"Y Wang","year":"2017","unstructured":"Wang Y, Alnwisi S, Ke M. The impact of mild, moderate, and severe visual field loss in glaucoma on patients\u2019 quality of life measured via the Glaucoma Quality of Life-15 Questionnaire: a meta-analysis. Medicine (Baltimore). 2017;96:e8019.","journal-title":"Medicine (Baltimore)"},{"key":"1248_CR11","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1016\/j.exer.2009.02.007","volume":"88","author":"ER Tamm","year":"2009","unstructured":"Tamm ER. The trabecular meshwork outflow pathways: structural and functional aspects. Exp Eye Res. 2009;88:648\u201355.","journal-title":"Exp Eye Res"},{"issue":"790\u20135","key":"1248_CR12","first-page":"e4","volume":"115","author":"KS Lim","year":"2008","unstructured":"Lim KS, Nau CB, O\u2019Byrne MM, Hodge DO, Toris CB, McLaren JW, et al. Mechanism of action of bimatoprost, latanoprost, and travoprost in healthy subjects. A crossover study. Ophthalmology. 2008;115(790\u20135):e4.","journal-title":"Ophthalmology"},{"key":"1248_CR13","first-page":"1514","volume":"42","author":"JW Kim","year":"2001","unstructured":"Kim JW, Lindsey JD, Wang N, Weinreb RN. Increased human scleral permeability with prostaglandin exposure. Invest Ophthalmol Vis Sci. 2001;42:1514\u201321.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"1248_CR14","doi-asserted-by":"publisher","first-page":"4419","DOI":"10.1167\/iovs.02-1281","volume":"44","author":"M Richter","year":"2003","unstructured":"Richter M, Krauss AH, Woodward DF, Lutjen-Drecoll E. Morphological changes in the anterior eye segment after long-term treatment with different receptor selective prostaglandin agonists and a prostamide. Invest Ophthalmol Vis Sci. 2003;44:4419\u201326.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"1248_CR15","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1089\/jop.2013.0179","volume":"30","author":"NS Winkler","year":"2014","unstructured":"Winkler NS, Fautsch MP. Effects of prostaglandin analogues on aqueous humor outflow pathways. J Ocul Pharmacol Ther. 2014;30:102\u20139.","journal-title":"J Ocul Pharmacol Ther"},{"key":"1248_CR16","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1016\/j.tips.2004.03.002","volume":"25","author":"DF Woodward","year":"2004","unstructured":"Woodward DF, Gil DW. The inflow and outflow of anti-glaucoma drugs. Trends Pharmacol Sci. 2004;25:238\u201341.","journal-title":"Trends Pharmacol Sci"},{"key":"1248_CR17","doi-asserted-by":"publisher","first-page":"3887","DOI":"10.1167\/iovs.06-0036","volume":"47","author":"DJ Oh","year":"2006","unstructured":"Oh DJ, Martin JL, Williams AJ, Russell P, Birk DE, Rhee DJ. Effect of latanoprost on the expression of matrix metalloproteinases and their tissue inhibitors in human trabecular meshwork cells. Invest Ophthalmol Vis Sci. 2006;47:3887\u201395.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"1248_CR18","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s12886-016-0202-8","volume":"16","author":"H Yamada","year":"2016","unstructured":"Yamada H, Yoneda M, Gosho M, Kato T, Zako M. Bimatoprost, latanoprost, and tafluprost induce differential expression of matrix metalloproteinases and tissue inhibitor of metalloproteinases. BMC Ophthalmol. 2016;16:26.","journal-title":"BMC Ophthalmol"},{"key":"1248_CR19","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1016\/j.ajo.2009.12.003","volume":"149","author":"LJ Katz","year":"2010","unstructured":"Katz LJ, Cohen JS, Batoosingh AL, Felix C, Shu V, Schiffman RM. Twelve-month, randomized, controlled trial of bimatoprost 0.01%, 0.0125%, and 0.03% in patients with glaucoma or ocular hypertension. Am J Ophthalmol. 2010;149:661\u201371.","journal-title":"Am J Ophthalmol"},{"key":"1248_CR20","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1016\/j.ajo.2007.06.012","volume":"144","author":"AL Robin","year":"2007","unstructured":"Robin AL, Novack GD, Covert DW, Crockett RS, Marcic TS. Adherence in glaucoma: objective measurements of once-daily and adjunctive medication use. Am J Ophthalmol. 2007;144:533\u201340.","journal-title":"Am J Ophthalmol"},{"key":"1248_CR21","doi-asserted-by":"crossref","first-page":"728","DOI":"10.18553\/jmcp.2009.15.9.728","volume":"15","author":"J Yeaw","year":"2009","unstructured":"Yeaw J, Benner JS, Walt JG, Sian S, Smith DB. Comparing adherence and persistence across 6 chronic medication classes. J Manag Care Pharm. 2009;15:728\u201340.","journal-title":"J Manag Care Pharm"},{"key":"1248_CR22","doi-asserted-by":"publisher","first-page":"2398","DOI":"10.1016\/j.ophtha.2011.05.013","volume":"118","author":"B Sleath","year":"2011","unstructured":"Sleath B, Blalock S, Covert D, Stone JL, Skinner AC, Muir K, et al. The relationship between glaucoma medication adherence, eye drop technique, and visual field defect severity. Ophthalmology. 2011;118:2398\u2013402.","journal-title":"Ophthalmology"},{"key":"1248_CR23","doi-asserted-by":"publisher","first-page":"441","DOI":"10.2147\/PPA.S23780","volume":"5","author":"G Reardon","year":"2011","unstructured":"Reardon G, Kotak S, Schwartz GF. Objective assessment of compliance and persistence among patients treated for glaucoma and ocular hypertension: a systematic review. Patient Prefer Adherence. 2011;5:441\u201363.","journal-title":"Patient Prefer Adherence"},{"key":"1248_CR24","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1185\/03007995.2013.833898","volume":"29","author":"GF Schwartz","year":"2013","unstructured":"Schwartz GF, Hollander DA, Williams JM. Evaluation of eye drop administration technique in patients with glaucoma or ocular hypertension. Curr Med Res Opin. 2013;29:1515\u201322.","journal-title":"Curr Med Res Opin"},{"key":"1248_CR25","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1097\/IJG.0b013e31819c4679","volume":"19","author":"JE Stryker","year":"2010","unstructured":"Stryker JE, Beck AD, Primo SA, Echt KV, Bundy L, Pretorius GC, et al. An exploratory study of factors influencing glaucoma treatment adherence. J Glaucoma. 2010;19:66\u201372.","journal-title":"J Glaucoma"},{"key":"1248_CR26","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1016\/j.ophtha.2015.03.026","volume":"122","author":"PA Newman-Casey","year":"2015","unstructured":"Newman-Casey PA, Robin AL, Blachley T, Farris K, Heisler M, Resnicow K, et al. The most common barriers to glaucoma medication adherence: a cross-sectional survey. Ophthalmology. 2015;122:1308\u201316.","journal-title":"Ophthalmology"},{"key":"1248_CR27","doi-asserted-by":"publisher","first-page":"2043","DOI":"10.1007\/s11095-010-0159-x","volume":"27","author":"SS Lee","year":"2010","unstructured":"Lee SS, Hughes P, Ross AD, Robinson MR. Biodegradable implants for sustained drug release in the eye. Pharm Res. 2010;27:2043\u201353.","journal-title":"Pharm Res"},{"key":"1248_CR28","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.ajo.2016.11.020","volume":"175","author":"RA Lewis","year":"2017","unstructured":"Lewis RA, Christie WC, Day DG, Craven ER, Walters T, Bejanian M, et al. Bimatoprost sustained-release implants for glaucoma therapy: 6-month results from a phase I\/II clinical trial. Am J Ophthalmol. 2017;175:137\u201347.","journal-title":"Am J Ophthalmol"},{"key":"1248_CR29","unstructured":"Craven ER, Walters T, Christie W, Bejanian M, Goodkin ML, Guo Q, Zhang J, Robinson MR, Ahmed IK. Phase 3 evaluation of Bimatoprost sustained-release implant in patients with glaucoma or ocular hypertension: results at primary database lock [abstract no. PA054-2019]. Presented at the American Academy of Ophthalmology 2019 meeting, San Francisco, CA, 12\u201315 October 2019. https:\/\/aao.scientificposters.com\/epsAbstractAAO.cfm?id=2. Accessed 23 Dec 2019."},{"key":"1248_CR30","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1089\/jop.2018.0067","volume":"35","author":"JR Seal","year":"2019","unstructured":"Seal JR, Robinson MR, Burke J, Bejanian M, Coote M, Attar M. Intracameral sustained-release bimatoprost implant delivers bimatoprost to target tissues with reduced drug exposure to off-target tissues. J Ocul Pharmacol Ther. 2019;35:50\u20137.","journal-title":"J Ocul Pharmacol Ther"},{"key":"1248_CR31","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1124\/jpet.102.047837","volume":"305","author":"DF Woodward","year":"2003","unstructured":"Woodward DF, Krauss AH, Chen J, Liang Y, Li C, Protzman CE, et al. Pharmacological characterization of a novel antiglaucoma agent, Bimatoprost (AGN 192024). J Pharmacol Exp Ther. 2003;305:772\u201385.","journal-title":"J Pharmacol Exp Ther"},{"key":"1248_CR32","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1016\/0014-4835(88)90043-7","volume":"47","author":"E Lutjen-Drecoll","year":"1988","unstructured":"Lutjen-Drecoll E, Tamm E. Morphological study of the anterior segment of cynomolgus monkey eyes following treatment with prostaglandin F2 alpha. Exp Eye Res. 1988;47:761\u20139.","journal-title":"Exp Eye Res"},{"key":"1248_CR33","doi-asserted-by":"publisher","first-page":"5984","DOI":"10.1167\/iovs.16-19734","volume":"57","author":"L De Groef","year":"2016","unstructured":"De Groef L, Andries L, Siwakoti A, Geeraerts E, Bollaerts I, Noterdaeme L, et al. Aberrant collagen composition of the trabecular meshwork results in reduced aqueous humor drainage and elevated IOP in MMP-9 null mice. Invest Ophthalmol Vis Sci. 2016;57:5984\u201395.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"1248_CR34","first-page":"2649","volume":"39","author":"JM Bradley","year":"1998","unstructured":"Bradley JM, Vranka J, Colvis CM, Conger DM, Alexander JP, Fisk AS, et al. Effect of matrix metalloproteinases activity on outflow in perfused human organ culture. Invest Ophthalmol Vis Sci. 1998;39:2649\u201358.","journal-title":"Investig Ophthalmol Vis Sci"},{"key":"1248_CR35","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.jconrel.2017.11.008","volume":"269","author":"J Kim","year":"2018","unstructured":"Kim J, Kudisch M, da Silva NRK, Asada H, Aya-Shibuya E, Bloomer MM, et al. Long-term intraocular pressure reduction with intracameral polycaprolactone glaucoma devices that deliver a novel anti-glaucoma agent. J Control Release. 2018;269:45\u201351.","journal-title":"J Control Release"},{"key":"1248_CR36","doi-asserted-by":"publisher","first-page":"4341","DOI":"10.1167\/iovs.16-19585","volume":"57","author":"J Kim","year":"2016","unstructured":"Kim J, Kudisch M, Mudumba S, Asada H, Aya-Shibuya E, Bhisitkul RB, et al. Biocompatibility and pharmacokinetic analysis of an intracameral polycaprolactone drug delivery implant for glaucoma. Invest Ophthalmol Vis Sci. 2016;57:4341\u20136.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"1248_CR37","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1097\/ICU.0000000000000334","volume":"28","author":"AA Aref","year":"2017","unstructured":"Aref AA. Sustained drug delivery for glaucoma: current data and future trends. Curr Opin Ophthalmol. 2017;28:169\u201374.","journal-title":"Curr Opin Ophthalmol"},{"key":"1248_CR38","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1016\/j.ophtha.2017.04.022","volume":"124","author":"JD Brandt","year":"2017","unstructured":"Brandt JD, DuBiner HB, Benza R, Sall KN, Walker GA, Semba CP. Long-term safety and efficacy of a sustained-release bimatoprost ocular ring. Ophthalmology. 2017;124:1565\u20136.","journal-title":"Ophthalmology"},{"key":"1248_CR39","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1016\/j.ophtha.2005.01.042","volume":"112","author":"R van der Valk","year":"2005","unstructured":"van der Valk R, Webers CA, Schouten JS, Zeegers MP, Hendrikse F, Prins MH. Intraocular pressure-lowering effects of all commonly used glaucoma drugs: a meta-analysis of randomized clinical trials. Ophthalmology. 2005;112:1177\u201385.","journal-title":"Ophthalmology"},{"key":"1248_CR40","unstructured":"United States Census Bureau. United States Census 2018: QuickFacts\u2014United States; 2018. https:\/\/www.census.gov\/quickfacts\/fact\/table\/US\/PST045218. Accessed Nov 1, 2019."}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-019-01248-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-019-01248-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-019-01248-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,10]],"date-time":"2021-08-10T17:55:21Z","timestamp":1628618121000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-019-01248-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,28]]},"references-count":40,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["1248"],"URL":"https:\/\/doi.org\/10.1007\/s40265-019-01248-0","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12,28]]},"assertion":[{"value":"28 December 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Institutional review board or independent ethics committee approval was obtained at each site before the study began, and the study was performed in compliance with good clinical practice, the principles of the Declaration of Helsinki, or the laws and regulations of the country in which the study was conducted (ClinicalTrials.gov registration number NCT01157364).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"All patients in this study provided written informed consent before undergoing any study-related procedure.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"This study was sponsored by Allergan plc (Dublin, Ireland). The study sponsor participated in the design of the study, data management, analysis and interpretation, and preparation, review, and approval of the manuscript.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"E. Randy Craven is a consultant for Aerie, Alcon, Allergan, Ivantis, Santen, and WL Gore and has received grant support from Allergan. Thomas Walters is a consultant for Allergan, Nicox, Ocular Therapeutix, and Sun. William C. Christie is a consultant for Allergan and Johnson & Johnson. Douglas G. Day is a consultant for Allergan. Richard A. Lewis is a consultant for Aerie, Alcon, Allergan, Aquesys, AVS, Envisia, Glaukos, Ivantis, Oculeve, PolyActiva, ViSci, and Zeiss. Margot L. Goodkin, Michelle Chen, Veronica Wangsadipura, Michael R. Robinson, and Marina Bejanian are Allergan employees.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}